Lead Sponsor

Regeneron Pharmaceuticals

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Adults ≥ 18 years of age with foveal center-involved macular edema (ME) secondary to BRVO diagnosed within 12 months before the screening visit
•2. ETDRS BCVA: letter score of 73 to 24 (20/40 to 20/320) in the study eye at screening and at day 1
•3. Provide signed informed consent

•1. Current bilateral manifestation of BRVO
•2. Uncontrolled glaucoma defined as ≥ 25 mmHg on optimal medical regimen, or previous filtration surgery in either the study eye or the fellow eye
•3. Insufficient clearing of macular hemorrhage that would prevent the patient from receiving laser treatment safely on day 1 (patients that meet this criterion may be rescreened once the macular hemorrhage resolves)
•4. Uncontrolled diabetes mellitus (DM)
•5. Previous use of intraocular corticosteroids or anti-angiogenic drugs in the study eye
•6. Use of periocular corticosteroids in the study eye within 3 months before day 1
•7. Use of intraocular or periocular corticosteroids or anti-angiogenic drugs in the fellow eye within 3 months before day 1
•8. Previous administration of systemic anti-angiogenic medications
•9. Panretinal scatter photocoagulation, sector laser photocoagulation, or macular grid photocoagulation in the study eye

Related studies

NCT05476926 · Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, and more

NCT05520177 · Branch Retinal Vein Occlusion

NCT04516278 · Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, and more

NCT06708637 · Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, and more

NCT03802630 · Branch Retinal Vein Occlusion

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)